Cytokinetics Stock Forecast for 2023 - 2025 - 2030

Updated on 02/05/2023

Stock Rating
10
Price Target
$60.00
Consensus
Outperform
Upside
33.30%
Analysts
0
Stock Rating
10
Upside
33.30%
Analysts
0
Price Target
$60.00

Cytokinetics Stock Forecast and Price Target

In recent months, notable analysts have provided yearlong price targets for Cytokinetics, with the average target coming in at $60.00. If it were to be achieved, this would result in a potential upside of approximately 33.3 percent from the most recent closing price in February, 2023. The high end is $80.00, and the low is $55.00. If you're interested in CYTK stock, it's important to compare it to other companies in the industry.

$60.00

33.30% Upside

Outperform
Outperform

Cytokinetics Fair Value Forecast for 2023 - 2025 - 2030

Cytokinetics's Price has seen growth In the last two years, going from $0.00 to $0.00 – a gain of 100.00% In the next year, analysts believe that Fair Value will reach $49.54 – an increase of 100.00%. For the next eight years, the forecast is forFair Value to grow by 100.00%.

2023 Fair Value Forecast
$49.54
2024 Fair Value Forecast
$55.08
2025 Fair Value Forecast
$61.24
2026 Fair Value Forecast
$68.10
2027 Fair Value Forecast
$75.72
2028 Fair Value Forecast
$84.19
2029 Fair Value Forecast
$93.61
2030 Fair Value Forecast
$104.09

Cytokinetics Revenue Forecast for 2023 - 2025 - 2030

Cytokinetics's Revenue has seen growth In the last two years, going from $26.87M to $70.43M – a gain of 162.11% According to 14 prominent analysts, Cytokinetics's Revenue will fall by 39.73% in the next year, reaching $42.45M. For the next eight years, the forecast is forRevenue to grow by 3378.26%.

2023 Rev Forecast
$0.04B
2024 Rev Forecast
$0.10B
2025 Rev Forecast
$0.35B
2026 Rev Forecast
$0.65B
2027 Rev Forecast
$1.05B
2028 Rev Forecast
$1.51B
2029 Rev Forecast
$2.07B
2030 Rev Forecast
$2.45B

Cytokinetics Dividend per Share Forecast for 2023 - 2025 - 2030

2023 DPS Forecast
$0.00
2024 DPS Forecast
$0.00
2025 DPS Forecast
$0.00
2026 DPS Forecast
$0.00
2027 DPS Forecast
$0.00
2028 DPS Forecast
$0.00
2029 DPS Forecast
$0.00
2030 DPS Forecast
$0.00

Cytokinetics Free Cash Flow Forecast for 2023 - 2025 - 2030

In the last two years, Cytokinetics's Free Cash Flow has increased by 104.63%, going from $-93.53M to $-191.39M. In the next year, analysts are expecting an increase in Free Cash Flow, predicting it will reach $-334.00M – an increase of 74.51%. According to professional forecasts, in 2030, Cytokinetics's Free Cash Flow will decrease by 953.75%, reaching $1.63B.

2023 FCF Forecast
$-334000000.00
2024 FCF Forecast
$-331330000.00
2025 FCF Forecast
$-313500000.00
2026 FCF Forecast
$-195500000.00
2027 FCF Forecast
$0.23B
2028 FCF Forecast
$0.82B
2029 FCF Forecast
$1.34B
2030 FCF Forecast
$1.63B

Cytokinetics Net Income Forecast for 2023 - 2025 - 2030

Cytokinetics's Net Income has grown in the last two years, jumping from $-121.69M to $-215.31M – an increase of 76.93%. In the next year, analysts predict that Net Income will reach $-420.57M – an increase of 95.33%. Professionals believe that By 2030, Cytokinetics's Net Income will fall to $1.29B– a 700.52% decrease from its current value.

2023 NI Forecast
$-420570000.00
2024 NI Forecast
$-386650000.00
2025 NI Forecast
$-86690000.00
2026 NI Forecast
$0.24B
2027 NI Forecast
$0.52B
2028 NI Forecast
$0.74B
2029 NI Forecast
$1.12B
2030 NI Forecast
$1.29B

Cytokinetics EBITDA Forecast for 2023 - 2025 - 2030

In the last two years, Cytokinetics's EBITDA has grown, increasing from $-97.57M to $-184.04M – an increase of 88.62%. For next year, the 4 analysts predict EBITDA of $-457.86M, which would mean an increase of 148.78%. Professionals believe that By 2030, Cytokinetics's EBITDA will fall to $742.24M – a 503.30% decrease from its current value.

2023 EBITDA Forecast
$-457860000.00
2024 EBITDA Forecast
$-441710000.00
2025 EBITDA Forecast
$-331590000.00
2026 EBITDA Forecast
$-80180000.00
2027 EBITDA Forecast
$0.23B
2028 EBITDA Forecast
$0.41B
2029 EBITDA Forecast
$0.69B
2030 EBITDA Forecast
$0.74B

Cytokinetics EBIT Forecast for 2023 - 2025 - 2030

Cytokinetics's EBIT has increased by 88.44% In the last two years, going from $-98.87M to $-186.31M. In the next year, analysts expect EBIT to reach $-428.69M – an increase of 130.10%. In 2030, professionals predict that Cytokinetics's EBIT will decrease by 800.93%, to $1.31B.

2023 EBIT Forecast
$-428690000.00
2024 EBIT Forecast
$-418000000.00
2025 EBIT Forecast
$-218230000.00
2026 EBIT Forecast
$-16450000.00
2027 EBIT Forecast
$0.27B
2028 EBIT Forecast
$0.58B
2029 EBIT Forecast
$1.03B
2030 EBIT Forecast
$1.31B

Cytokinetics EPS Price Prediction Forecast for 2023 - 2025 - 2030

Cytokinetics's EPS has seen growth In the last two years, going from $-2.11 to $-2.80 – a gain of 32.70% In the next year, analysts believe that EPS will reach $-4.70 – an increase of 67.86%. By 2030, professionals believe that Cytokinetics's EPS will decrease by 322.14%, reaching $6.22 – a concerning trend for the company.

2023 EPS Forecast
$-4.70
2024 EPS Forecast
$-4.41
2025 EPS Forecast
$-2.71
2026 EPS Forecast
$-1.53
2027 EPS Forecast
$0.64
2028 EPS Forecast
$2.50
2029 EPS Forecast
$4.82
2030 EPS Forecast
$6.22